London · Delayed Price · Currency is GBP · Price in GBX Oxford Instruments Earnings Call Transcripts
Fiscal Year 2026
-
Delivered strong full-year results with margin and cash flow improvements, driven by robust order growth in Advanced Technologies and operational efficiencies in Imaging & Analysis. Strategic transformation, including divestments and restructuring, positions the group for accelerated growth and higher margins in FY 2027.
-
Despite H1 disruptions from tariffs and U.S. funding cuts, order momentum and operational improvements position the group for strong H2 growth, margin recovery, and continued investment in technology. Share buybacks and a robust balance sheet support future growth.
Fiscal Year 2025
-
Strong revenue and profit growth, margin expansion, and robust cash flow were achieved, driven by semiconductor and materials analysis strength. The NanoScience business was sold for GBP 60 million, enabling a GBP 50 million buyback and further margin improvement, while FX and macro uncertainties remain key risks.
-
Delivered 10.4% constant currency revenue growth, with strong performance in semiconductors and materials analysis offsetting healthcare weakness. Strategic reorganization and operational improvements are driving efficiency, and a robust order book supports a positive full-year outlook despite FX headwinds.
Fiscal Year 2024
-
Revenue grew 9.8% and adjusted operating profit rose 3.7% at constant currency, driven by strong performance in material analysis, healthcare, and semiconductors. A new divisional structure and operational improvements target 20%+ margins and sustainable growth, despite China-related headwinds.